• Expanded scope of “identical predicate” equivalence. Devices that can demonstrate substantial equivalence to a legally marketed device in China — including through comparative performance testing — are now eligible for exemption even if they incorporate minor material or design variations.
• New “fast-track exemption” for imported devices with prior CE or FDA clearance. Foreign-registered devices that have been on the market for at least three years in a recognized jurisdiction can submit a streamlined equivalence dossier and bypass the NMPA’s full clinical review queue.
• Mandatory post-market surveillance (PMS) requirements. Exempted device holders must submit annual PMS reports and, for implantable low-risk devices, quarterly adverse event summaries. Failure to comply triggers immediate suspension of the exemption status.

The policy specifically targets three registration bottlenecks: the 12- to 18-month clinical trial enrollment period that previously blocked market entry, the 6-month data translation and submission phase for foreign trial reports, and the repetitive in-country testing that added both cost and delay.

2. Impact on Medical Device Registration Timeline and Costs

To visualize the shift, consider a mid-sized U.S. diagnostic device manufacturer entering China with a Class II blood glucose monitoring system. Under the pre-2025 framework, the company faced an average of 24 months to registration. Under the new exemption pathway, the same device can achieve NMPA registration in approximately 10 months — a reduction of 58 percent.

Cost implications

The cost savings are equally dramatic. A full China-based clinical trial for a Class II device can range from RMB 1.5 million to RMB 5 million, depending on site numbers and patient enrollment. The exemption pathway eliminates that expense entirely, replacing it with a comparative performance testing budget of roughly RMB 200,000 to RMB 500,000. For a portfolio of five similar devices, the aggregate savings exceed RMB 10 million.

Timeline comparison: two real scenarios

Scenario A (full clinical trial pathway, Class II implantable): EU manufacturer of a titanium bone screw. No predicate device registered in China. The company spent 8 months identifying and contracting with three clinical trial sites, 14 months enrolling 120 patients, 4 months data analysis, and 6 months NMPA review. Total: 32 months.

Scenario B (exemption pathway, Class II diagnostic reagent): U.S. manufacturer of a hepatitis B test kit. FDA-cleared for 5 years. Submitted a comparative performance dossier with 200 samples against a registered Chinese device. NMPA review: 6 months. Total: 7 months.

The difference is not merely operational — it fundamentally changes the go-to-market calculus for foreign device companies that previously viewed China registration as a multi-year investment with uncertain returns.

3. Strategic Implications for Foreign Medical Device Companies

Foreign executives evaluating China market entry often face a core strategic decision: register a single flagship device first to test the regulatory waters, or launch a portfolio to leverage economies of scale. The exemption policy upends this binary.

Decision framework

If your device is a low-risk Class II product with a clear predicate device already registered in China — including devices from competitors or earlier-generation models — choose the exemption pathway by allocating 60 to 90 days to build a comparative performance dossier that meets NMPA’s new equivalence standards. If your device introduces novel technology, novel materials, or a new intended use without a predicate — or if it requires human implant studies — choose the full clinical trial pathway, but budget for the longer timeline and consider parallel submission of a 临床试验方案 (clinical trial protocol, línchuáng shìyàn fāng’àn) to shorten review cycles by up to 4 months.

Portfolio strategy implications

Because the exemption policy covers a broader range of categories, companies with five or more eligible devices can achieve portfolio-level registration in roughly the same time that a single device previously required. The NMPA allows bundled submissions for devices that share the same predicate, meaning a single equivalence dossier can support multiple variants. This reduces per-device regulatory cost from roughly RMB 800,000 to RMB 150,000.

Risk considerations

While the exemption pathway reduces upfront clinical risk, it shifts risk to the post-market phase. Companies must now invest in a robust PMS infrastructure — a data management system, a Chinese-language complaint handling process, and a local agent who can respond to NMPA inquiries within 48 hours. Foreign companies that underestimate this requirement have already faced compliance warnings in Q1 2025.

4. Common Pitfalls in Applying for Clinical Trial Exemption

Despite the policy’s clear benefits, several foreign device companies have encountered avoidable setbacks. The following represent the three most frequent pitfalls observed in early 2025 filings.